Unknown

Dataset Information

0

Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis.


ABSTRACT:

Background

The potential prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabine-based chemotherapy is variably reported.

Objective

The objective of this study was to conduct a systematic review of literature evaluating human equilibrative nucleoside transporter1 expression as a prognostic factor in pancreatic cancer receiving gemcitabine-based chemotherapy and to conduct a subsequent meta-analysis to quantify the overall prognostic effect.

Methods

Related studies were identified and evaluated for quality through multiple search strategies. Only studies analyzing pancreatic cancer receiving gemcitabine-based chemotherapy were eligible for inclusion. Data were collected from studies comparing overall, disease-free and progression-free survival (OS, DFS and PFS) in patients with low human equilibrative nucleoside transporter1 levels and those having high levels. The hazard ratio (HR) and its 95% confidence interval (95%CI) were used to assess the strength of associations. Hazard ratios greater than 1 reflect adverse survival associated with low human equilibrative nucleoside transporter1 levels.

Results

A total of 12 studies (n?=?875) were involved in this meta-analysis (12 for OS, 5 for DFS, 3 for PFS). For overall and disease-free survival, the pooled HRs of human equilibrative nucleoside transporter1 were significant at 2.93 (95% confidence interval [95% CI], 2.37-3.64) and 2.67 (95% CI, 1.87-3.81), respectively. For progression-free survival, the pooled HR in higher human equilibrative nucleoside transporter1 expression in pancreatic cancer receiving gemcitabine-based chemotherapy was 2.76 (95% CI, 1.76-4.34). No evidence of significant heterogeneity or publication bias was seen in any of these studies.

Conclusion

These results support the case for a low human equilibrative nucleoside transporter1 level representing a significant and reproducible marker of adverse prognosis in pancreatic cancer receiving gemcitabine-based chemotherapy.

SUBMITTER: Liu ZQ 

PROVIDER: S-EPMC3903621 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis.

Liu Zhu-Qing ZQ   Han Ying-Chao YC   Zhang Xi X   Chu Li L   Fang Jue-Min JM   Zhao Hua-Xin HX   Chen Yi-Jing YJ   Xu Qing Q  

PloS one 20140127 1


<h4>Background</h4>The potential prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabine-based chemotherapy is variably reported.<h4>Objective</h4>The objective of this study was to conduct a systematic review of literature evaluating human equilibrative nucleoside transporter1 expression as a prognostic factor in pancreatic cancer receiving gemcitabine-based chemotherapy and to conduct a subsequent meta-analysis to quantify the overall prognost  ...[more]

Similar Datasets

| S-EPMC10619907 | biostudies-literature
| S-EPMC5359181 | biostudies-literature
| S-EPMC3173155 | biostudies-literature
| S-EPMC7318791 | biostudies-literature
| S-EPMC4196761 | biostudies-literature
| S-EPMC6296552 | biostudies-literature
| S-EPMC5494679 | biostudies-other
| S-EPMC2670673 | biostudies-literature
| S-EPMC4368391 | biostudies-literature
| S-EPMC2934698 | biostudies-literature